Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (705) 705
Publication (120) 120
Patent (77) 77
Book / eBook (10) 10
Book Chapter (7) 7
Book Review (3) 3
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (470) 470
oncology (326) 326
index medicus (218) 218
female (217) 217
male (208) 208
middle aged (186) 186
aged (169) 169
adult (168) 168
pharmacology & pharmacy (149) 149
cancer (140) 140
neoplasms - drug therapy (139) 139
article (98) 98
pharmacokinetics (82) 82
aged, 80 and over (70) 70
pharmacogenetics (70) 70
research (70) 70
antineoplastic agents - therapeutic use (66) 66
chemotherapy (65) 65
biochemistry (64) 64
chemistry (64) 64
beer (63) 63
compositions or test papers therefor (63) 63
condition-responsive control in microbiological orenzymological processes (63) 63
enzymology (63) 63
measuring or testing processes involving enzymes, nucleicacids or microorganisms (63) 63
metallurgy (63) 63
microbiology (63) 63
mutation or genetic engineering (63) 63
processes of preparing such compositions (63) 63
spirits (63) 63
vinegar (63) 63
wine (63) 63
antineoplastic agents - pharmacokinetics (61) 61
dose-response relationship, drug (54) 54
treatment outcome (54) 54
genotype (53) 53
camptothecin - analogs & derivatives (49) 49
care and treatment (49) 49
antineoplastic agents - administration & dosage (47) 47
antineoplastic agents - adverse effects (47) 47
antineoplastic combined chemotherapy protocols - therapeutic use (45) 45
drug administration schedule (45) 45
glucuronosyltransferase - genetics (45) 45
animals (42) 42
medicine & public health (42) 42
phase-i (40) 40
pharmacology/toxicology (39) 39
analysis (37) 37
antineoplastic combined chemotherapy protocols - adverse effects (36) 36
cell lung-cancer (36) 36
clinical trials (36) 36
irinotecan (36) 36
area under curve (35) 35
genetics & heredity (35) 35
human necessities (35) 35
hygiene (35) 35
medical or veterinary science (35) 35
preparations for medical, dental, or toilet purposes (35) 35
antineoplastic agents - pharmacology (34) 34
compositions thereof (33) 33
culture media (33) 33
microorganisms or enzymes (33) 33
propagating, preserving or maintaining microorganisms (33) 33
research design (33) 33
therapy (33) 33
tumors (33) 33
genetic aspects (32) 32
toxicity (32) 32
antineoplastic agents (31) 31
clinical-trials (31) 31
infusions, intravenous (31) 31
pharmacology (31) 31
administration, oral (30) 30
drug therapy (30) 30
paclitaxel (30) 30
clinical trials as topic (29) 29
neoplasms - metabolism (29) 29
united states (29) 29
abridged index medicus (28) 28
breast-cancer (28) 28
health aspects (28) 28
maximum tolerated dose (27) 27
neoplasms - genetics (26) 26
neoplasms - therapy (26) 26
cancer research (25) 25
drug interactions (25) 25
neutropenia - chemically induced (25) 25
polymorphisms (25) 25
trial (25) 25
active metabolite (24) 24
expression (24) 24
glucuronidation (24) 24
models, biological (24) 24
phase i (24) 24
lung neoplasms - drug therapy (23) 23
solid tumors (23) 23
camptothecin - pharmacokinetics (22) 22
clinical trials, phase i as topic (22) 22
dosage and administration (22) 22
drugs (22) 22
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (795) 795
French (32) 32
German (14) 14
Croatian (2) 2
Danish (2) 2
Greek (2) 2
Slovenian (2) 2
Arabic (1) 1
Chinese (1) 1
Hungarian (1) 1
Lithuanian (1) 1
Polish (1) 1
Portuguese (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text The Role of Early-Phase Design-Letter
by Ratain, MJ
CLINICAL CANCER RESEARCH, ISSN 1078-0432, 05/2019, Volume 25, Issue 10, pp. 3190 - 3190
ONCOLOGY | TARGETED THERAPIES
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text The molecular profiling lottery: More accuracy, less precision, and no cost
by Ratain, Mark J
Clinical Cancer Research, ISSN 1078-0432, 02/2019, Volume 25, Issue 4, pp. 1136 - 1138
The concept of complete molecular profiling to select investigational treatment options is appealing, theoretically allowing the matching of patients to... 
ONCOLOGY
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Forecasting unanticipated consequences of "the sunshine act": Mostly cloudy
by Ratain, Mark J
Journal of Clinical Oncology, ISSN 0732-183X, 08/2014, Volume 32, Issue 22, pp. 2293 - 2295
ONCOLOGY | Patient Protection and Affordable Care Act - legislation & jurisprudence | Conflict of Interest - legislation & jurisprudence | United States | Drug Industry - legislation & jurisprudence | Humans | Physicians - legislation & jurisprudence | Physicians - economics | Fees and Charges - legislation & jurisprudence
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Time is money: Optimizing the scheduling of Nivolumab
by Ratain, Mark J and Goldstein, Daniel A
Journal of Clinical Oncology, ISSN 0732-183X, 11/2018, Volume 36, Issue 31, pp. 3074 - 3076
ANTIBODY | THERAPY | ONCOLOGY | SAFETY | EXPOSURE-RESPONSE ANALYSES
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Immunotherapy and the A2A Adenosine Receptor: A Confounding Brew
by Strohbehn, Garth W and Ratain, Mark J
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 09/2019, Volume 106, Issue 3, pp. 498 - 500
CAFFEINE | PHARMACOLOGY & PHARMACY
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Targeted therapies: redefining the primary objective of phase I oncology trials
by Ratain, Mark J
Nature reviews. Clinical oncology, ISSN 1759-4774, 2014, Volume 11, Issue 9, pp. 503 - 504
Cytotoxic agents are conventionally dosed on the basis of the maximum tolerated dose defined in phase I trials. A study assessing adverse events in over 2,000... 
ONCOLOGY | INHIBITOR | CANCER | Antineoplastic Agents - adverse effects | Humans | Antineoplastic Agents - pharmacokinetics | Drug Approval | Antineoplastic Agents - administration & dosage | Molecular Targeted Therapy | Research Design | Clinical Trials, Phase I as Topic | Clinical Trials, Phase II as Topic
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Alternative dosing regimens for atezolizumab: right dose, wrong frequency
by Goldstein, Daniel A and Ratain, Mark J
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 12/2019, Volume 84, Issue 6, pp. 1153 - 1155
The population pharmacokinetics of atezolizumab demonstrate that the trough concentrations are well above the putative target of 6 µg/ml. Thus, alternative... 
Medicine & Public Health | Schedule | Pharmacoeconomics | Oncology | Cancer Research | Pharmacology/Toxicology | Pharmacokinetics | Atezolizumab | Medical policy | Public health | Dosing | Schedules | Chemotherapy | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Redefining the primary objective of phase I oncology trials (vol 11, pg 503, 2014)
by Ratain, MJ
NATURE REVIEWS CLINICAL ONCOLOGY, ISSN 1759-4774, 03/2015, Volume 12, Issue 3, pp. 126 - 126
ONCOLOGY
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Prolonged Pharmacokinetic Interaction Between Capecitabine and a CYP2C9 Substrate, Celecoxib
by Ramírez, Jacqueline and House, Larry K and Karrison, Theodore G and Janisch, Linda A and Turcich, Michelle and Salgia, Ravi and Ratain, Mark J and Sharma, Manish R
The Journal of Clinical Pharmacology, ISSN 0091-2700, 12/2019, Volume 59, Issue 12, pp. 1632 - 1640
This study investigated the time course and magnitude of the pharmacokinetic interaction between capecitabine and the cytochrome P450 (CYP) 2C9 substrate... 
pharmacokinetics | capecitabine | CYP2C9 | celecoxib | drug‐drug interaction | Cytochrome | Plasma | Warfarin | Cytochrome P450 | Drug interactions | Pharmacology | Exposure | Celecoxib | Substrates | Confidence intervals | Equivalence | Drug interaction | Cytochromes P450 | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Tumour heterogeneity in the clinic
by Bedard, Philippe L and Hansen, Aaron R and Ratain, Mark J and Siu, Lillian L
Nature, ISSN 0028-0836, 2013, Volume 501, Issue 7467, pp. 355 - 364
Recent therapeutic advances in oncology have been driven by the identification of tumour genotype variations between patients, called interpatient... 
CELL LUNG CANCERS | COLORECTAL-CANCER | MULTIDISCIPLINARY SCIENCES | FACTOR RECEPTOR 2 | METASTATIC BREAST-CANCER | INTRATUMOR HETEROGENEITY | ACQUIRED-RESISTANCE | HER2 GENE AMPLIFICATION | ANTI-EGFR THERAPY | IN-SITU | MUTATIONAL EVOLUTION | Neoplasms - therapy | Neoplasms - genetics | Time Factors | Neoplasm Metastasis - pathology | Humans | Longitudinal Studies - methods | Gene Expression Profiling - methods | Neoplasms - diagnosis | Clinical Trials as Topic - methods | Clonal Evolution - genetics | Neoplasms - pathology | Care and treatment | Genetic aspects | Research | Cancer | Studies | Breast cancer | Mutation | Cancer therapies | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Oncology Micro-Cap Stocks: Caveat Emptor
by Adam Feuerstein and Mark J Ratain
Journal of the National Cancer Institute, ISSN 0027-8874, 10/2011, Volume 103, Issue 20, p. 1488
Feuerstein and Ratain suggest these trends reflect investors' perceptions of these companies, as indicated by market capitalization. At 120 days before the... 
Stock prices | Investors | Oncology | Capitalization
Journal Article
Details down arrow
12. Full Text Enhancing the Visibility and Prestige of Clinical Pharmacology as a Medical Subspecialty
by Ratain, Mark J
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 11/2019, Volume 106, Issue 5, pp. 914 - 915
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Outline of oncology therapeutics
by Ratain, Mark J., 1954 and Skosey, Consuelo and Tempero, Margaret
2001, ISBN 0721681239, xix, 266
Antineoplastic Agents | Chemotherapy | Drug Therapy | Cancer
Book
Details down arrow
14. Full Text Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
by Kwak, Eunice L and Bang, Yung-Jue and Camidge, D. Ross and Shaw, Alice T and Solomon, Benjamin and Maki, Robert G and Ou, Sai-Hong I and Dezube, Bruce J and Jänne, Pasi A and Costa, Daniel B and Varella-Garcia, Marileila and Kim, Woo-Ho and Lynch, Thomas J and Fidias, Panos and Stubbs, Hannah and Engelman, Jeffrey A and Sequist, Lecia V and Tan, WeiWei and Gandhi, Leena and Mino-Kenudson, Mari and Wei, Greg C and Shreeve, S. Martin and Ratain, Mark J and Settleman, Jeffrey and Christensen, James G and Haber, Daniel A and Wilner, Keith and Salgia, Ravi and Shapiro, Geoffrey I and Clark, Jeffrey W and Iafrate, A. John
The New England Journal of Medicine, ISSN 0028-4793, 10/2010, Volume 363, Issue 18, pp. 1693 - 1703
A small group of patients with non–small-cell lung cancer have genetic lesions that activate anaplastic lymphoma kinase (ALK). Crizotinib, an orally... 
ALK | MEDICINE, GENERAL & INTERNAL | GEFITINIB | EML4-ALK FUSION GENE | 2ND-LINE TREATMENT | PHASE-II | IDENTIFICATION | TUMORS | ACTIVATING MUTATIONS | EGFR | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Microtubule-Associated Proteins - genetics | Humans | Middle Aged | Receptors, Growth Factor - antagonists & inhibitors | Lung Neoplasms - pathology | Male | Protein Kinase Inhibitors - adverse effects | Protein-Tyrosine Kinases - genetics | Pyridines - adverse effects | Serine Endopeptidases - genetics | Cell Cycle Proteins - genetics | Adult | Female | Pyrazoles - adverse effects | Pyridines - therapeutic use | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Pyridines - administration & dosage | Administration, Oral | Carcinoma, Non-Small-Cell Lung - genetics | Proto-Oncogene Proteins c-met - antagonists & inhibitors | Kaplan-Meier Estimate | In Situ Hybridization, Fluorescence | Receptor Protein-Tyrosine Kinases | Disease Progression | Protein Kinase Inhibitors - administration & dosage | Pyrazoles - administration & dosage | Oncogene Proteins, Fusion - genetics | Protein Kinase Inhibitors - therapeutic use | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Protein-Tyrosine Kinases - antagonists & inhibitors | Tyrosine | Care and treatment | Lung cancer, Small cell | Genetic aspects | Diagnosis | Health aspects | Phosphotransferases | Lymphomas | Pharmaceutical industry | Lung cancer | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text Cancer pharmacogenomics: Strategies and challenges
by Wheeler, Heather E and Maitland, Michael L and Dolan, M. Eileen and Cox, Nancy J and Ratain, Mark J
Nature Reviews Genetics, ISSN 1471-0056, 01/2013, Volume 14, Issue 1, pp. 23 - 34
Genetic variation influences the response of an individual to drug treatments. Understanding this variation has the potential to make therapy safer and more... 
STATISTICAL-METHODS | TAMOXIFEN RESPONSE | GENETIC-VARIATION | LUNG-CANCER | GENETICS & HEREDITY | RESPONSIVE BREAST-CANCER | COMMON SNPS EXPLAIN | CYP2D6 GENOTYPE | POSTMENOPAUSAL WOMEN | IMPLEMENTATION CONSORTIUM | GENOME-WIDE ASSOCIATION | Pharmacogenetics - methods | Genome-Wide Association Study | Reproducibility of Results | Neoplasms - genetics | Signal Transduction | Antineoplastic Agents - adverse effects | Humans | Germ-Line Mutation | Antineoplastic Agents - therapeutic use | Clinical Trials as Topic | Research Design | Neoplasms - drug therapy | Care and treatment | Pharmacogenetics | Genetic aspects | Research | Genetic variation | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text Measuring response in a post-RECIST world: from black and white to shades of grey
by Michaelis, Laura C and Ratain, Mark J
Nature Reviews Cancer, ISSN 1474-175X, 05/2006, Volume 6, Issue 5, pp. 409 - 414
The unprecedented pace of therapeutic development in oncology has created a climate in which the traditional methods of evaluating agent activity might no... 
CRITERIA | PHASE-II TRIALS | DESIGN | SOLID TUMORS | ONCOLOGY | ANTICANCER AGENTS | CLINICAL-TRIALS | END-POINTS | CANCER | APPROVAL PROCESS | Humans | Treatment Outcome | Antineoplastic Agents - therapeutic use | Clinical Trials as Topic | Neoplasms - pathology | Research Design | Disease Progression | Neoplasms - drug therapy | Antimitotic agents | Care and treatment | Dosage and administration | Genetic aspects | Research | Antineoplastic agents | Methods | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
17. Participation in Cancer Pharmacogenomic Studies: A Study of 8456 Patients Registered to Clinical Trials in the Cancer and Leukemia Group B (Alliance)
by Lynn G Dressler and Allison M Deal and Kouros Owzar and Dorothy Watson and Kathleen Donahue and Paula N Friedman and Mark J Ratain and Howard L McLeod
Journal of the National Cancer Institute, ISSN 0027-8874, 10/2015, Volume 107, Issue 10, p. 1
  Clinically annotated specimens from cancer clinical trial participants offer an opportunity for discovery and validation of pharmacogenomic findings. The... 
Genomics | Leukemia | Clinical trials | Pharmacology | Multivariate analysis | Optimization | Cancer
Journal Article
Details down arrow
18. Full Text The Molecular Profiling Lottery: More Accuracy, Less Precision, and No Cost
by Ratain, Mark J
Clinical cancer research : an official journal of the American Association for Cancer Research, ISSN 1078-0432, 12/2018
The concept of complete molecular profiling to select investigational treatment options is appealing, theoretically allowing the matching of patients to... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
19. Full Text Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer
by Razelle Kurzrock and Steven I. Sherman and Douglas W. Ball and Arlene A. Forastiere and Roger B. Cohen and Ranee Mehra and David G. Pfister and Ezra E.W. Cohen and Linda Janisch and Forlisa Nauling and David S. Hong and Chaan S. Ng and Lei Ye and Robert F. Gagel and John Frye and Thomas Müller and Mark J. Ratain and Ravi Salgia
Journal of Clinical Oncology, ISSN 0732-183X, 07/2011, Volume 29, Issue 19, pp. 2660 - 2666
Purpose XL184 (cabozantinib) is a potent inhibitor of MET, vascular endothelial growth factor receptor 2 (VEGFR2), and RET, with robust antiangiogenic,... 
GROWTH-FACTOR RECEPTOR | GLIOBLASTOMA | ONCOLOGY | VEGF | PHASE-II | RET PROTOONCOGENE MUTATIONS | SORAFENIB | CARCINOMA | EXPRESSION | MET | CHEMOTHERAPY | Anilides - therapeutic use | Proto-Oncogene Proteins c-ret - metabolism | Administration, Oral | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Maximum Tolerated Dose | Neoplasm Metastasis | Carcinoma, Neuroendocrine | Thyroid Neoplasms - drug therapy | Aged, 80 and over | Adult | Female | Aged | Protein-Tyrosine Kinases - antagonists & inhibitors | Pyridines - therapeutic use | Index Medicus | Original Reports | Faze
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights